Inclusion Criteria:

- Joined the study voluntary and signed informed consent form

- Age 18-70，both genders.

- Nasopharyngeal cancer was confirmed by pathology.

- Nasopharyngeal cancer 2008 Stages: Ⅲ/Ⅳa.

- Primary lesions can measurable.

- Karnofsky Performance Scale >70.

- Life expectancy of more than 6 months.

- Use of an effective contraceptive method for women when there is a risk of pregnancy
during the study.

- Haemoglobin≥100g/L ,WBC ≥4×109/L, platelet count≥100×109/L

- Hepatic function:ALAT、ASAT< 1.5 x ULN, TBIL< 1.5 x ULN

- Renal function: Creatinine < 1.5 x ULN

Exclusion Criteria:

- Evidence of distant metastasis

- Primary lesions or lymph node have been operated (except of operation for biopsy)

- Previous radiotherapy

- Received other anti EGFR monoclonal antibody treatment

- Previous chemotherapy or immunization therapy

- Other malignant tumor (except of Non-melanoma Skin Cancer or carcinoma in situ of
cervix)

- Participation in other interventional clinical trials within 1 month

- Peripheral neuropathy is more than I stage

- Pregnant or breast-feeding women and women who refused to take contraceptive method

- History of serious allergic or allergy

- History of Serious lung or heart disease

- Refused or can't signed informed consent form

- Drug abuse or alcohol addiction

- Personality or psychiatric disease, and persons without capacity for civil conduct or
persons with limited capacity for civil conduct